Conduit Pharmaceuticals enters joint development agreement with Manoira

Conduit Pharmaceuticals (CDT) announced that it has entered into a joint development agreement with Manoira Corporation, a privately held specialty animal health company specializing in proprietary reformulation technologies to create novel therapeutics for veterinary and livestock applications. Under the terms of the joint development agreement, Manoira will evaluate Conduit’s AZD1656 and AZD5658, both clinical-stage glucokinase activators, in animal health indications, providing Conduit with high-value translational data across human and veterinary applications. Manoira will focus its initial evaluation of AZD1656 in animal osteoarthritis, a common degenerative joint condition in companion animals, to generate preclinical data that will better inform Conduit’s human clinical programs. This cost-efficient collaboration allows Conduit to accelerate its understanding of AZD1656’s mechanism of action, safety profile, and potential efficacy across species, while retaining 100% ownership of all data and intellectual property generated relating to AZD1656 and AZD5658 for human applications.